LENZ Therapeutics, Inc. financial data

Symbol
LENZ on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
201 Lomas Santa Fe Drive, Suite 300, Solana Beach, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Graphite Bio, Inc. (to 3/19/2024)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.31K % -33.9%
Debt-to-equity 11.2 %
Return On Equity -89.9 % -158%
Return On Assets -64.7 % -170%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 27.5M shares -52.6%
Common Stock, Shares, Outstanding 27.5M shares -52.6%
Entity Public Float 151M USD +0.47%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 27.2M shares +1285%
Weighted Average Number of Shares Outstanding, Diluted 27.2M shares +1285%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 16.1M USD -72.4%
General and Administrative Expense 41M USD +24.7%
Operating Income (Loss) -131M USD -76.8%
Nonoperating Income (Expense) 15.6M USD +372%
Net Income (Loss) Attributable to Parent -115M USD -63%
Earnings Per Share, Basic 17.2 USD/shares +96.1%
Earnings Per Share, Diluted 17.2 USD/shares +96.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 41M USD -77.6%
Cash, Cash Equivalents, and Short-term Investments 217M USD -7.18%
Assets, Current 221M USD -7.57%
Property, Plant and Equipment, Net 372K USD -97%
Operating Lease, Right-of-Use Asset 1.53M USD -88.4%
Other Assets, Noncurrent 1.4M USD
Assets 224M USD -15.9%
Accounts Payable, Current 2.76M USD -26.4%
Employee-related Liabilities, Current 2.19M USD +15.3%
Accrued Liabilities, Current 4.95M USD
Liabilities, Current 7.71M USD -38.5%
Operating Lease, Liability, Noncurrent 953K USD -98.1%
Other Liabilities, Noncurrent 64K USD
Liabilities 8.73M USD -86%
Accumulated Other Comprehensive Income (Loss), Net of Tax 523K USD
Retained Earnings (Accumulated Deficit) -132M USD +61.5%
Stockholders' Equity Attributable to Parent 215M USD
Liabilities and Equity 224M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9M USD -87%
Net Cash Provided by (Used in) Financing Activities 171M USD +106%
Net Cash Provided by (Used in) Investing Activities 18M USD
Common Stock, Shares Authorized 300M shares 0%
Common Stock, Shares, Issued 27.5M shares -52.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 165M USD +135%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 41.2M USD -3.94%
Deferred Tax Assets, Valuation Allowance 67.6M USD +77.4%
Deferred Tax Assets, Gross 67.7M USD +72.3%
Operating Lease, Liability 1.43M USD -97.3%
Depreciation 2.4M USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -9.63M USD +49%
Lessee, Operating Lease, Liability, to be Paid 1.6M USD -98.2%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 625K USD -81.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 577K USD -93.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 151K USD -98.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 168K USD -99.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 511K USD -93.8%
Deferred Tax Assets, Operating Loss Carryforwards 30.8M USD +93.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 3.56M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 361K USD -95.7%
Operating Lease, Payments 1.75M USD +32.5%
Additional Paid in Capital 347M USD -36.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 73 USD -93.8%
Share-based Payment Arrangement, Expense 14.5M USD +226%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%